Lyka Labs Ltd. — Regulatory Filings 2020

Jun 5, 2020

==> picture [453 x 78] intentionally omitted <==

05[th] June, 2020

The BSE Limited The National Stock Exchange of India Ltd 1st floor, New Trading Ring Exchange Plaza, 5[th] Floor Rotunda Bldg, P.J Towers Plot No. C/1, G. Block Dalal Street, Mumbai -400 001 Bandra Kurla Complex Bandra (East), Mumbai – 400 051 Script Code: 500259 Script Code: LYKALABS

Dear Sir/Madam,

Sub: Disclosure under regulation 30 of SEBI (Listing Obligations and Disclosures Requirements), 2015

Re: Impact of COVID-19

1. Due to COVID-19 epidemic, the Government has declared Locked down but allowed the pharma company to operate the factory, however, the presence of workers at a factory was very low, as a result, the production at Ankleshwar Factory has been badly affected. The plant was running at 40% of its capacity.

2. There has been interruption in supply of raw material and packing material to the Factory.

3. The parties who have placed orders with the Company have deferred the execution of orders, as a result, the sales has been affected and created liquidity crunch.

4. The administrative office and R&D center of the Company at Mumbai has been closed due to locked down and at present, it is partially operating.

5. The Company has to bear interest cost and fixed overheads by way of rent of the Office premises and R&D center affecting liquidity position.

6. The performance of the Company continuing to be affected during locked down.

We request you to take the same on record.

Thanking You, Yours faithfully,

==> picture [89 x 37] intentionally omitted <==

==> picture [71 x 58] intentionally omitted <==

Piyush Hindia Company Secretary & Compliance Officer

==> picture [452 x 41] intentionally omitted <==

CIN: L24230GJ1976PLC008738